Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases.
Chan
C C
CC
Department of Pharmacology, Merck Frosst Centre for Therapeutic Research Kirkland, Quebec, Canada.
Rodger
I W
IW
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001859:Bone Neoplasms / Q000201:enzymology / Q000473:pathology; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D015232:Dinoprostone / Q000096:biosynthesis; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007189:Indans / Q000494:pharmacology / Q000633:toxicity; D007213:Indomethacin / Q000494:pharmacology / Q000633:toxicity; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D008565:Membrane Proteins; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D012516:Osteosarcoma / Q000201:enzymology / Q000473:pathology; D011451:Prostaglandin-Endoperoxide Synthases / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D012453:Saimiri; D013276:Stomach Ulcer / Q000139:chemically induced; D013379:Substrate Specificity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007189:Indans; D007527:Isoenzymes; C093700:L 745337; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C496513:Ptgs1 protein, rat; D015232:Dinoprostone; D007213:Indomethacin